Evidence map›Paper›PMID 35992828›Full record

ArticleFrontiers in oncology2022

External validation study of endometrial cancer preoperative risk stratification model (ENDORISK).

Petra Vinklerová, Petra Ovesná, Jitka Hausnerová, Johanna M A Pijnenborg, Peter J F Lucas, Casper Reijnen, Stephanie Vrede, Vít Weinberger

Registry-linked trialAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07200466 (ENDORISK Clinical Implementation Study), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07200466 narecruitingnot on this mapstarted 2025, after this paper: background citation

ENDORISK Clinical Implementation Study

TypeinterventionalSponsorRadboud University Medical CenterRan2025 to 2032Enrolled735ConditionsEndometrial CancerArmsENDORISK personalized risk assesment for lymph node metastases in endometrial cancer.
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Petra VinklerováDepartment of Gynecology and Obstetrics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Petra OvesnáInstitute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czechia.
Jitka HausnerováDepartment of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Johanna M A PijnenborgDepartment of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, Netherlands.
Peter J F LucasDepartment of Data Science, University of Twente, Enschede, Netherlands.
Casper ReijnenDepartment of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands.
Stephanie VredeDepartment of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, Netherlands.
Vít WeinbergerDepartment of Gynecology and Obstetrics, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Among industrialized countries, endometrial cancer is a common malignancy with generally an excellent outcome. To personalize medicine, we ideally compile as much information as possible concerning patient prognosis prior to effecting an appropriate treatment decision. Endometrial cancer preoperative risk stratification (ENDORISK) is a machine learning-based computational Bayesian networks model that predicts lymph node metastasis and 5-year disease-specific survival potential with percentual probability. Our objective included validating ENDORISK effectiveness in our patient cohort, assessing its application in the current use of sentinel node biopsy, and verifying its accuracy in advanced stages. Methods: The ENDORISK model was evaluated with a retrospective cohort of 425 patients from the University Hospital Brno, Czech Republic. Two hundred ninety-nine patients were involved in our disease-specific survival analysis; 226 cases with known lymph node status were available for lymph node metastasis analysis. Patients were included undergoing either pelvic lymph node dissection ( Results: The area under the curve was 0.84 (95% confidence interval [CI], 0.77-0.9) for lymph node metastasis analysis and 0.86 (95% CI, 0.79-0.93) for 5-year disease-specific survival evaluation, indicating quite positive concordance between prediction and reality. Calibration plots to visualize results demonstrated an outstanding predictive value for low-risk cancers (grades 1-2), whereas outcomes were underestimated among high-risk patients (grade 3), especially in disease-specific survival. This phenomenon was even more obvious when patients were subclassified according to FIGO clinical stages. Conclusions: Our data confirmed ENDORISK model's laudable predictive ability, particularly among patients with a low risk of lymph node metastasis and expected favorable survival. For high-risk and/or advanced stages, the ENDORISK network needs to be additionally trained/improved.

Indexed as

Bayesian networks modeldisease-specific survivalendometrial cancerlymph node metastasisprognosisrisk stratificationsentinel node biopsy

Identifiers

PMID35992828
PMCPMC9381832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.